---
id: ITE-2024-124
type: ITE
year: 2024
number: 124
created: 2025-08-10 13:35:41.699720
tags:
- ITE
- question
- ITE-2024
- 2024-exam
answer: D
topic: Family Medicine
related_articles:
- title: PubMed Entry
  path: 2022/2022-09-ibrexafungerp-brexafemme-for-the-treatment-of-vulvovaginal-c.md
  similarity: 0.2
  link: '[[2022-09-ibrexafungerp-brexafemme-for-the-treatment-of-vulvovaginal-c|PubMed
    Entry]]'
- title: PubMed Entry
  path: 2022/2022-07-abametapir-074-xeglyze-for-the-treatment-of-head-lice.md
  similarity: 0.2
  link: '[[2022-07-abametapir-074-xeglyze-for-the-treatment-of-head-lice|PubMed Entry]]'
- title: PubMed Entry
  path: 2022/2022-12-another-study-fails-to-find-platelet-rich-plasma-injections.md
  similarity: 0.2
  link: '[[2022-12-another-study-fails-to-find-platelet-rich-plasma-injections|PubMed
    Entry]]'
- title: PubMed Entry
  path: 2022/2022-07-treatment-of-chagas-disease-in-breastfeeding-dyads.md
  similarity: 0.2
  link: '[[2022-07-treatment-of-chagas-disease-in-breastfeeding-dyads|PubMed Entry]]'
- title: PubMed Entry
  path: 2022/2022-08-cannabis-for-treatment-of-chronic-pain.md
  similarity: 0.2
  link: '[[2022-08-cannabis-for-treatment-of-chronic-pain|PubMed Entry]]'
topics:
- Family Medicine
related_articles_2023_2025:
- title: graham center family medicine research
  path: 2023/12/2023-12-graham-center-family-medicine-research.md
  similarity: 0.308
  link: '[[2023/12/2023-12-graham-center-family-medicine-research|graham center family
    medicine research]]'
- title: editorial ai family medicine puulications
  path: 2025/01/2025-01-editorial-ai-family-medicine-publications.md
  similarity: 0.306
  link: '[[2025/01/2025-01-editorial-ai-family-medicine-publications|editorial ai
    family medicine puulications]]'
- title: graham center family medicine residency applications
  path: 2023/08/2023-08-graham-center-family-medicine-residency-applications.md
  similarity: 0.305
  link: '[[2023/08/2023-08-graham-center-family-medicine-residency-applications|graham
    center family medicine residency applications]]'
last_updated: '2025-08-10T20:26:58.693890'
---

# Question ITE-2024-124

## Question
Which one of the following is an effective topical treatment for postinflammatory hyperpigmentation 
in persons with Fitzpatrick skin types IV, V, and VI?

## Answer Choices
**A)** Ammonium lactate 12% lotion (Lac -Hydrin)
**B)** Clindamycin 1% gel (Clindagel)
**C)** Hydrocortisone 1% cream (Cortizone -10)
**D)** Hydroquinone 4% cream
**E)** Metronidazole 0.75% gel

## Correct Answer
**D**

## Explanation
There are a variety of topical therapies for the treatment of postinflammatory hyperpigmentation in persons with Fitzpatrick skin types IV, V, and VI, including hydroquinone, fluocinolone/hydroquinone/tretinoin, and azelaic acid. Adapalene, tretinoin, and tazarotene are also acceptable options for hyperpigmentation associated with acne. Ammonium lactate 12% lotion, clindamycin 1% gel, hydrocortisone 1% cream, and metronidazole 0.75% gel are not effective topical therapies for postinflammatory hyperpigmentat ion in such patients.

## References
Frazier WT, Proddutur S, Swope K. Common dermatologic conditions in skin of color. Am Fam Physician . 2023;107(1):26 -34.

## Related AAFP Articles
- [[2022-09-ibrexafungerp-brexafemme-for-the-treatment-of-vulvovaginal-c|PubMed Entry]] (Relevance: 20%)
- [[2022-07-abametapir-074-xeglyze-for-the-treatment-of-head-lice|PubMed Entry]] (Relevance: 20%)
- [[2022-12-another-study-fails-to-find-platelet-rich-plasma-injections|PubMed Entry]] (Relevance: 20%)
- [[2022-07-treatment-of-chagas-disease-in-breastfeeding-dyads|PubMed Entry]] (Relevance: 20%)
- [[2022-08-cannabis-for-treatment-of-chronic-pain|PubMed Entry]] (Relevance: 20%)

---
*Source: 2024 ABFM In-Training Examination*